Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05159700 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor and Advanced Solid Malignancies, sponsored by Zhuhai Yufan Biotechnologies Co..
- Active
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 6
- Study locations
NCT05159700: Active Phase 1 study of Advanced Solid Tumor and Advanced Solid Malignancies, sponsored by Zhuhai Yufan Biotechnologies Co..
NCT05159700 is a Phase 1 study of Advanced Solid Tumor and Advanced Solid Malignancies that is active but no longer recruiting, run by Zhuhai Yufan Biotechnologies Co.. The registered enrollment target is 39 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (80% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05159700, a Phase 1 study of Advanced Solid Tumor and Advanced Solid Malignancies, is active but no longer recruiting, sponsored by Zhuhai Yufan Biotechnologies Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a Phase I, multicenter, open-label, 3+3 dose escalation study to determine the safety and preliminary efficacy of PRJ1-3024 in subjects with relapsed/refractory solid tumors.
Primary Outcome
Safety listings and pharmacokinetic listings will be used for evaluation
Conditions Studied
Interventions
- DRUG PRJ1-3024
Study Locations (6)
Texas
- NEXT Oncology - Austin
- Mays Cancer Center - San Antonio
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Florida
- Sarah Cannon Research Institute at Florida Cancer Specialists - Orlando
Ohio
- Christ Hospital - Cincinnati
Virginia
- NEXT Oncology - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2026-06-29 |
| Phase | Phase 1 |
What the registry record for NCT05159700 still lists
NCT05159700 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which PRJ1-3024 is the first listed.
NCT05159700 lists 6 locations in 5 states (Texas, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT05159700 about?
NCT05159700 is a clinical study titled "A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors". This is a Phase I, multicenter, open-label, 3+3 dose escalation study to determine the safety and preliminary efficacy of PRJ1-3024 in subjects with relapsed/refractory solid tumors.
What is the current status of trial NCT05159700?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2022-03-31. Estimated completion is 2026-06-29.
What conditions does trial NCT05159700 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Advanced Solid Malignancies.
What interventions are being tested in trial NCT05159700?
The interventions under investigation include: PRJ1-3024 (DRUG).
Who is sponsoring clinical trial NCT05159700?
This trial is sponsored by Zhuhai Yufan Biotechnologies Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05159700 being conducted?
This trial has 6 study locations across Colorado, Florida, Ohio, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05159700's enrollment target sits among peer trials
39 171st of 189 higher than 18 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI